14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
SLS vs BOLD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, SELLAS Life Sciences Group, Inc. (SLS) is the stronger overall head-to-head candidate over Boundless Bio, Inc. (BOLD) in the Tradestie Institutional Equity Comparison Engine, winning 2–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). SLS carries a Unified Composite Score of 33.6/100 (SELL) at $13.66 (N/M Forward P/E, 0.0% operating margin), whereas BOLD carries 36.8/100 (SELL) at $2.32 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While BOLD currently prints a higher short-term Unified Composite Score (36.8/100 SELL vs. SLS 33.6/100 SELL), SLS captures the overall institutional head-to-head verdict (2–4 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (-82.5% vs. +0.0% YoY).
Defensive Composite Rating Caution: Although SLS compares more favorably head-to-head, both SLS (33.6/100 SELL) and BOLD (36.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: SLS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 56.5); meanwhile BOLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SLS vs BOLD. Trailing 12-month operating profitability (SLS 0.0% vs BOLD 0.0%) and valuation multiples (SLS N/M vs BOLD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $56.2M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SLS vs BOLD Key Questions & Quantitative Answers
As of Nov 20, 2026, SELLAS Life Sciences Group, Inc. (SLS) is the stronger overall head-to-head candidate over Boundless Bio, Inc. (BOLD) in the Tradestie Institutional Equity Comparison Engine, winning 2–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). SLS carries a Unified Composite Score of 33.6/100 (SELL) at $13.66 (N/M Forward P/E, 0.0% operating margin), whereas BOLD carries 36.8/100 (SELL) at $2.32 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While BOLD currently prints a higher short-term Unified Composite Score (36.8/100 SELL vs. SLS 33.6/100 SELL), SLS captures the overall institutional head-to-head verdict (2–4 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (-82.5% vs. +0.0% YoY). Defensive Composite Rating Caution: Although SLS compares more favorably head-to-head, both SLS (33.6/100 SELL) and BOLD (36.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: SLS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 56.5); meanwhile BOLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BOLD leads the Growth & Scale pillar: SLS posts -82.5% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with BOLD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SLS generates N/A in USD-normalized revenue versus N/A for BOLD. In operating R&D and SG&A reinvestment, SLS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BOLD.
SLS and BOLD trade at balanced relative valuation multiples. SLS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas BOLD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SLS (-40.3% ROE) versus BOLD (-64.6% ROE) capital efficiency.
In options market volatility and institutional positioning, SLS carries 109.5% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.45x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.91β · 550% Vol realized risk). By comparison, BOLD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.08β · 28% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.